ArticleAmerican journal of respiratory and critical care medicine2019
Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis.Current allergy and asthma reports · 2022Pooled it
- Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis.The Journal of allergy and clinical immunology · 2021Trial
- Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2020Trial
- Article
- Review
- Integrated Immune, Epithelial and Lipid Pathways in NSAID-Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- A Narrative Review of Recent Developments in Aspirin Therapy After Desensitization in NSAIDs-Exacerbated Respiratory Disease.Journal of inflammation research · 2026Review
- New insights into the mechanisms of aspirin-exacerbated respiratory disease.Current opinion in allergy and clinical immunology · 2025Review
- Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?The journal of allergy and clinical immunology. In practice · 2024Review
- Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023Article
- Aspirin-exacerbated respiratory disease: Updates in the era of biologics.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Mechanistic and clinical updates in AERD: 2021-2022.The Journal of allergy and clinical immunology · 2023Article
- Updates on immune mechanisms in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2023Review
- Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Article
- Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.Clinical and translational allergy · 2021Review
- Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021Review
- Leukotriene DThe Journal of allergy and clinical immunology · 2021Article
- Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Observational
- The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.The Journal of allergy and clinical immunology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Katherine N CahillDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0002-8549-1835
Jing CuiDivision of Rheumatology, Immunology, and Allergy and.
Parul KothariDivision of Rheumatology, Immunology, and Allergy and.
Katherine MurphyDivision of Rheumatology, Immunology, and Allergy and.
Benjamin A RabyDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Joseph SingerDivision of Rheumatology, Immunology, and Allergy and.
Elliot IsraelDivision of Rheumatology, Immunology, and Allergy and.
Joshua A BoyceDivision of Rheumatology, Immunology, and Allergy and.
Tanya M LaidlawDivision of Rheumatology, Immunology, and Allergy and.
Harvard University · USBrigham and Women's Hospital · USENT and Allergy · USVanderbilt University · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MTherapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Maria Gutierrez-Arcelus · 2011 to 2026
$29.1MIMMUNOLOGIC BASIS OF RESISTANCE AND HYPERSENSITIVITYT32AI007306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett, Joshua A Boyce · 1985 to 2026
$12.2MRegulation of Pulmonary Prostaglandins by Leukotriene E4R01AI078908 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2009 to 2025
$8.8MEicosanoid Networks in Aspirin HypersensitivityR01AI136041 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2018 to 2026
$5.4MCysLT and P2Y Receptors in Lung InflammationR37AI052353 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2013 to 2022
$5.2MProstaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory DiseaseR01HL128241 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LAIDLAW, TANYA MARIA · 2015 to 2019
$2.2MOptimizing EP receptor subtype targeting for asthma therapyR01HL136209 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI BIRRELL, MARK A, BOYCE, JOSHUA A · 2017 to 2020
$2.2MTHE ROLE OF PROSTAGLANDIN D2 IN THE RESPIRATORY SYMPTOMS OF ASPIRIN EXACERBATED RESPIRATORY DISEASEK23AI118804 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAHILL, KATHERINE N · 2015 to 2019
$951kThe inflammatory role of the platelet in aspirin-exacerbated respiratory disease.K23HL111113 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LAIDLAW, TANYA MARIA · 2012 to 2016
$721kNCATS NIH HHS UL1 TR001102NHLBI NIH HHS K23 HL111113NHLBI NIH HHS R01 HL128241NHLBI NIH HHS R01 HL136209NIAID NIH HHS K23 AI118804NIAID NIH HHS R01 AI078908NIAID NIH HHS R01 AI136041NIAID NIH HHS R37 AI052353NIAID NIH HHS T32 AI007306NIAID NIH HHS U19 AI095219
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinAsthma, Aspirin-InducedBiomarkersDrug HypersensitivityFemaleHumansMaleMiddle AgedProspective StudiesReceptors, LeukotrieneRespiratory Tract InfectionsAnti-Inflammatory Agents, Non-SteroidalAspirinBiomarkersReceptors, Leukotrieneaspirin-exacerbated respiratory diseaseaspirin-tolerant asthmacysteinyl leukotrienesmast celltype 2 inflammation
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.